Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ken Griffin And Citadel Further Increase Stake In PHH Corporation (PHH)

Ken Griffin is still optimistic about the prospects of PHH Corporation (NYSE:PHHand has further increased his investment in the company. As reported in a recent filing with the Securities and Exchange Commission, Griffin and his fund, Citadel Investment Group, have upped their stake by 1.54 million shares, taking it to 5.51 million shares or 9.6% of the company’s common stock. At the end of June, Citadel and Griffin have more than doubled their holding of PHH Corporation (NYSE:PHH).

CITADEL INVESTMENT GROUP

Daniel Lewis, the manager of Orange Capital, is also a fan of PHH Corporation (NYSE:PHH) and has increased their holding of the stock by 3% during the first quarter of 2014. In its latest 13F filing, Orange Capital has reported ownership of 3.45 million shares. Emanuel J. Friedman is another manager who likes this stock, having initiated a new position for his fund during the same period. EJF Capital has built a 4.18 million shares position according to its latest 13F report. Larry Robbins, the manager of Glenview Capital, is also keeping tabs, with his fund reportedly holding 2.8 million shares.

Disclosure: none.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!